Rockland Immunochemicals

Biomolecule detection, characterization and analysis

www.rockland.com

About Rockland Immunochemicals

Established in 1962, Rockland Immunochemicals develops antibodies, immunological reagents and bioanalytical solutions that support the detection, characterization and analysis of biomolecules. The company combines expertise in antibody production, protein science and assay development to provide tools for life science research, drug discovery and biopharmaceutical development. Its capabilities span custom antibody generation, recombinant antibody development, protein and antibody characterization, antibody modification and analytical assay development. Rockland’s technologies support applications including immunodetection, protein analysis, biomarker research, therapeutic development, nucleic acid research and bioanalytical testing.

Rockland offers an extensive portfolio of primary and secondary antibodies, proteins, peptides, blood-derived products, supporting reagents, cell lysates, assay kits and specialised immunodetection tools. Product families such as TrueBlot® reagents are designed to improve antibody-based detection workflows, while ModDetect® panels enable the analysis of nucleic acid modifications independent of sequence, format or location. The company also develops reagents and assays for biotherapeutic and oligonucleotide programmes, including immunogenicity and bioanalytical applications. These products support workflows including Western blotting, immunohistochemistry, ELISA, immunofluorescence, protein characterisation and assay validation.

Europa Biosite subsidiaries distribute Rockland Immunochemicals products across Austria, Belgium, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Sweden, Switzerland and the United Kingdom.